FDA Approves Aucatzyl for Adults With Relapsed or Refractory B-Cell Precursor ALL

The FDA approved Aucatzyl, a CD19-directed genetically modified autologous T-cell immunotherapy, for adults with ...

NOVEMBER 12, 2024